{"id":"W2609430257","doi":"10.1093/annonc/mdx173","title":"Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"University of California, San Francisco; University of Warwick; Cancer Research UK; Sanofi","keywords":"Medicine; Epirubicin; Docetaxel; Bevacizumab; Fluorouracil; Cyclophosphamide; Oncology; Internal medicine; Chemotherapy; Breast cancer; Disease; Surgery; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001779082,0.000237551,0.0005302229,0.00002599943,0.0002349842,0.00002755512,0.0002183956,0.0001245461,0.00000767613],"category_scores_gemma":[0.0001538027,0.0002062272,0.00007809035,0.00002181893,0.0002443753,0.00001605686,0.0002137028,0.00004173912,4.447807e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006486371,"about_ca_system_score_gemma":0.0001732184,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008446224,"about_ca_topic_score_gemma":0.001535741,"domain_scores_codex":[0.9986899,0.00004344995,0.0002328938,0.0005041556,0.0001131696,0.0004163557],"domain_scores_gemma":[0.9987243,0.0001154008,0.0002884522,0.0004308192,0.0002017466,0.0002392602],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6554926,0.0009786555,0.05815854,0.00024914,0.003419984,0.00003171746,0.002312893,0.00001941843,0.02387459,0.0001121256,0.08295844,0.1723919],"study_design_scores_gemma":[0.1355418,0.01869557,0.7534552,0.00009725088,0.0003320111,0.00002061765,0.0003350827,0.00001030794,0.01427303,0.0009826692,0.07547113,0.0007853965],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870653,0.001165727,0.00002809166,0.00666854,0.0001586933,0.001213516,0.003585452,0.000007237127,0.0001074915],"genre_scores_gemma":[0.9959725,0.001155617,0.000402491,0.0004576615,0.0002186413,0.001087872,0.0000549433,0.00003336116,0.0006169181],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6952966,"threshold_uncertainty_score":0.8409699,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02595071290210165,"score_gpt":0.3272912708754922,"score_spread":0.3013405579733905,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}